IRVINE, Calif., Nov. 25, 2022 /CNW/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, is proud to announce the Health Canada license of the Forma-I to address the symptoms of dry eye disease due to Meibomian gland dysfunction (MGD). Forma-I is intended for use in the periorbital area and eyelids and relieves inflammation of meibomian glands and eye irritation.
MGD is a major cause of ocular discomfort, and 86% of dry eye patients demonstrate signs of MGD1. The North American dry eye market size reached $2.4 billion2 in 2021. This critical Canadian certification opens opportunities for InMode to provide a non-drug alternative for millions of MGD and dry eye sufferers.
InMode's Forma-I is an innovative thermal technology that delivers targeted bipolar radiofrequency energy to small, delicate ocular areas. Treatments are quick and easy and performed safely in-office.
Shakil Lakhani, President of InMode, North America, commented, "We are proud to deliver a medical solution that will benefit millions of dry eye disease sufferers. This once again shows InMode's commitment to help patients improve their quality of life. We look forward to adding this new innovative technology to our product portfolio."
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically-accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
1 Lemp,M.A., Cornea, Distribution of aqueous–deficient and evaporative dry eye in a clinic–based patient cohort: a retrospective study
2 IMARC, North America Dry Eye Syndrome Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027
| Last Trade: | US$16.60 |
| Daily Change: | -0.42 -2.47 |
| Daily Volume: | 191,735 |
| Market Cap: | US$1.270B |
September 04, 2024 August 06, 2024 July 31, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
